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1. Introduction   
Research in stem cell biology has the potential to dramatically alter the way we understand 
the vast complexity and coordination that is required for an organism to develop and 
function. The creation of therapeutic tools that will inevitably accompany these discoveries 
in this field of research may completely revolutionize our approach to medicine in the 21st 
century.  
In this chapter we will examine one facet of stem cell research that holds great potential to 
improve the quality of life for millions of individuals; the study of osteogenesis from 
pluripotent stem cells. Despite its overt rigid structure, which provides mechanical support 
and protective functions, bone is a highly dynamic tissue that is tightly regulated to serve 
multiple roles in the body. Bone tissue is constantly being remodeled by the actions of the 
osteoblasts, the bone forming cells, and the osteoclasts, the bone resorbing cells. The 
improper balance of these cells can result in a number of bone-related and 
osteodegenerative diseases. Osteoporosis, for example, is estimated to effect 75 million 
individuals in Europe, Japan and the US alone, and thus the potential benefits of 
understanding the processes regulating osteogenesis may be quite far reaching.  
Despite the similarity of the bone tissues found in the adult mammalian skeleton, there are 
three different sources from which bone is derived in the developing embryo (Fig. 1). Two 
of these bone origins are from mesodermal progenitors, where cells from either the lateral 
plate or paraxial mesoderm contribute to the appendicular or axial skeleton, respectively. 
The third origin of bone tissue can be traced back to ectodermal cells where neural crest 
progenitors differentiate into many of the bones within the craniofacial region. Differences 
in the origin in bone are also paralleled in differences seen in the bone formation process. 
Most bones of mesodermal origin develop via the process of endochondral bone formation, 
whereas the bones of ectodermal origin form by a process called intramembranous bone 
formation. These processes differ most generally in the series of cell differentiations that 
lead to the mature tissue. In endochondral bone formation the mesenchymal progenitors 
differentiate into chondrocytes, which lay down the cartilaginous framework that is 
eventually replaced by the mineralized matrix of invading osteoblasts, while the 
chondrocytes undergo apoptosis. In intramembranous bone formation, the progenitors 
differentiate directly into osteoblasts. In addition, mature bone tissues house adult stem cell 
niches, such as those composed of mesenchymal or hematopoietic stem cells. These cells are 
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the source for diverse cell types throughout the life of the organism and are critical for 
normal maintenance and overall physiology.  
 
 
Fig. 1. Embryonic origins of bone tissue 
While it is widely accepted that pluripotent stem cells have the capability to give rise to 
osteoblasts, it has only recently been examined whether they do so through a mesodermal 
route or through progenitors with neural crest characteristics. This chapter will provide a 
review of the current understanding of the different progenitors that contribute to the 
aforementioned bone formation processes and regulatory networks known to play critical 
roles in these cells. It will further examine the experimental manipulations in stem cell 
culture systems that have allowed us to derive neural crest and mesodermal type 
osteoprogenitors in vitro. However, it remains elusive whether a neural crest type progenitor 
and a mesodermal progenitor will have the same capacity to repair bone when transplanted 
or whether one will be superior to the other in a certain transplantation site. In order to 
systematically assess the influence of the type of progenitor and the transplantation site as 
well as the process of bone formation that is typically used as repair mechanism in a 
particular transplantation site, this chapter therefore also summarizes bone tissue 
engineering studies that have been undertaken using these diverse progenitors and that will 
bring us closer to eventual clinical applications that this exciting field of research will 
provide.   
2. Pluripotent stem cells to bone 
Both in vitro and in vivo studies continue to elucidate the developmental program that 
pluripotent stem cells take to their eventual differentiated states. One such program is the 
development of bone tissue; and research in this field has already made a positive impact on 
the lives of individuals in various clinical trials (Giordano et al., 2007). However, before 
these applications become commonplace in the medical field, further study is required to 
improve both our understanding and methodologies. This chapter seeks to give a broad 
overview of a diverse range of topics, from differentiation of pluripotent stem cells along 
osteogenic lineages, some current approaches in applying stem cell based bone engineering 
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for potential clinical applications, and concluding with a discussion of different bone origins 
and their respective developmental pathways.  
2.1 Embryonic stem cells 
Pluripotent stem cells can be distinguished from adult stem cells based on their nature of 
origin, but first and foremost based on their more versatile differentiation capability. This 
unsurpassed differentiation capability is known as pluripotency, the potential to generate 
cell types from the three embryonic germ layers: the mesoderm, the ectoderm and the 
endoderm. One class of pluripotent stem cells, the embryonic stem cells (ESCs) have been 
under fervent ethical debate since their initial derivation. The crux of this debate can be 
attributed to their source being a cluster of cells found in the blastocyst, an early pre-
implantation embryonic stage. This cluster of cells, the inner cell mass (ICM), is established 
directly after the developing embryo has gone through the first fate decision, in which the 
trophoectoderm secedes from the ICM. While this outer trophoectodermal layer of the 
blastocyst eventually gives rise to the placenta, the in vivo fate of the ICM is to develop into 
the embryo proper, which contains cell types of the three germ layers. Mirroring this 
capability of the ICM, isolated ESCs also have the capacity to give rise to cell types of all 
three germ layers when differentiated in vitro (Itskovitz-Eldor et al., 2000).  
ESCs were first derived from mouse blastocysts (Evans and Kaufman, 1981; Martin, 1981) 
and since then their derivation has been reported from a number of mammals including: 
hamster, rabbit and rat (Doetschman et al., 1988; Giles et al., 1993; Iannaccone et al., 1994).  
Although these alternative rodent ESC lines have never gained recognition as model 
systems, their utilization continues to provide insights into stem cell biology. As for primate 
ESC derivation, the initial challenges that plagued the field for years were finally overcome 
by Thomson et al. (1995), and this study laid the ground for the establishment of human 
ESCs by the same team just shortly before the turn of the century (Thomson et al., 1998).  
In addition to the pluripotent nature, it is their second characteristic of being capable of 
unlimited proliferation that ESCs first became an attractive cell source for regenerative 
therapies. This propagation in the undifferentiated state can be supported in culture with 
the addition of leukemia inhibitory factor (LIF) (Williams et al., 1988). Since LIF is inefficient 
in maintaining the undifferentiated state in human ESCs, the molecular cues needed maybe 
released by murine embryonic fibroblast feeder layers, which both human ESCs and murine 
ESCs can be grown on (Evans and Kaufman, 1981; Martin, 1981; Thomson et al., 1998). In 
feeder-independent conditions, basic fibroblast growth factor (bFGF) is able to maintain the 
pluripotent state of human ESCs (Amit et al., 2003).  
2.2 Differentiation of ESCs into bone cells  
Historically the developmental program that pluripotent stem cells take to form bone tissue 
was first elucidated using murine ESCs. Buttery and coworkers were the first to show that 
mESCs maintained in medium supplemented with beta-glycerophosphate and ascorbic acid 
had mineralized in culture, a hallmark feature of bone tissue formation (Buttery et al., 2001). 
In the past decade, numerous protocols have then been established that allow ESC 
differentiation into bone and cartilage and their characteristic cell types, the osteoblasts and 
osteoclasts as well as the chondocytes. The studies that describe formation of osteoblasts 
typically all assess the ability of the cells to secrete an organic matrix composed of collagen 
type I (COL I) and proteoglycans, the deposition of inorganic hydroxyapatite and the 
expression of osteoblast-specific genes (Davis et al., 2011; Handschel et al., 2008; Shimko et 
al., 2004).  
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One difference between these protocols however, is the choice of additional osteogenic 
inducers. While beta-glycerophosphate and ascorbic acid are absolutely necessary for the 
cells to calcify, the additional supplementation of either dexamethasone, retinoic acid or 
1,25alpha (OH)2 vitamin D3 (VD3) each can significantly increase the amount of bone 
nodules and expression of osteogenic markers in both mouse and human ESC cultures 
(Buttery et al., 2001; Phillips et al., 2001; Sottile et al., 2003; zur Nieden et al., 2003).  
Similar to endochondral bone formation in the embryo, osteogenesis from ESCs in vitro can 
be direct or the future bone can at first undergo a chondrocyte phase. Both processes have 
been described for ESCs. For example, during ESC in vitro intramembranous ossification, 
osteoblasts would be specified through a mesenchymal precursor and then directly into the 
osteoblastic fate. In this case, markers for hypertrophic chondrocytes should be absent or 
should only be minimally expressed. In turn, ESC differentiation would model embryonal 
endochondral ossification when ESCs would first differentiate into chondrocytes, then 
undergo hypertrophy and give way to osteoprogenitors that calcify. Hegert and colleagues, 
supported by data from our group, have shown that chondrogenic ESC cultures indeed can 
be manipulated to calcify, whereby such ossification results in a lower calcium content of 
the matrix then the direct (non chondrocyte-mediated) differentiation (Hegert et al., 2002; 
zur Nieden et al., 2005). This direct chondrocytic differentiation is mediated by growth 
factors of the transforming growth factor family, including bone morphogenic proteins and 
TGF1 (Kramer et al., 2000; Hegert et al.,  2002; zur Nieden et al., 2005; Toh et al., 2007). 
Under such treatment the cartilage-specific transcription factors Sox9 and scleraxis are up-
regulated at early stages of differentiation (Kramer et al., 2002, 2005; zur Nieden et al., 2005). 
The addition of BMP also increased the formation of cartilaginous matrix, comprised of 
collagen, proteoglycans and ECM proteins and expression of collagen mRNAs found in 
cartilage, such as collagen type II and collagen type X, the latter being indicative of 
chondrocytes undergoing hypertrophy (Kielty et al., 1985). ESC cultures containing such 
hypertrophic chondrocytes also initiate expression of osteoblast-specific mRNAs. This 
overlap of the chondrocyte-specific and the osteoblast- specific differentiation program 
suggest that ESCs may be undergoing the endochondral bone formation process.  
In addition to growth factors and chemicals that direct differentiation through the 
endochondral or intramembranous route, different physical means have also been utilized to 
induce ESC differentiation into bone. While murine ESCs are typically grown into small (i.e. 
approximately 300-400 µm) agglomerates of differentiating cells called embryoid bodies (EBs) 
(Trettner et al., 2011), as the first stage of differentiation, human ESCs can alternatively be 
induced to differentiate by overgrowing colonies on a plate (Karp et al., 2006). Further 
osteogenic differentiation can be observed when intact EBs or dissociated EB cells are cultured 
in the presence of osteogenic supplements (Buttery et al., 2001; Cao et al., 2005; Chaudhry et 
al., 2004; zur Nieden et al., 2003). Woll and coworkers trypsinized mouse EBs into single cell 
suspensions and plated those at very low clonal density (Woll et al., 2006). They reported that 
approximately 60-80% of single-cell derived colony formation exhibited matrix mineralization 
as determined by von Kossa staining. Further qPCR analysis of osteoblast markers supported 
the potential of these cells to undergo osteogenesis, although there was heterogeneity between 
colonies in expression of these specific markers. Despite this heterogeneity between these 
individual colonies, the clonal expansion from a single cell offers an easy approach to dissect 
the differentiation pathway leading to bone cell formation. 
This seems to be of particular importance as ESCs can be lead to differentiate from 
pluripotency into mesenchyme and subsequently bone, whereby mesenchyme may be 
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specified either from a mesodermal or neural crest derived origin. More recent studies have 
indeed reported the generation of mesenchymal stem cell like cells from ESCs as well as the 
isolation of progenitors with osteogenic properties that were mesoderm or neural crest 
derived (Aihara et al., 2010; Olivier et al., 2006; Sakurai et al., 2006; Trivedi and Hematti, 
2007).  
A few days into the differentiation, ESCs will express T-Brachyury, a gene that is typically 
transcribed in the primitive streak when the early embryo undergoes gastrulation to 
establish the three germ layers (Beddington et al., 1992). The primitive streak contains cells 
with mesendodermal character, a subpopulation of cells that can later become osteoblasts. 
T-Brachyury expression is often used to characterize the output of differentiating 
mesendoderm (Gadue et al., 2006; Nakanishi et al., 2009) and is thus also informative to the 
very early differentiation events of osteogenesis. Similarly, modeled after the early lineage 
decisions in vivo, activin and nodal induction may be used to enhance the percentage of 
mesendodermal cells positive for Goosecoid (Gsc), E-cadherin, and platelet-derived growth 
factor receptor alpha (PDGFR) (Tada et al., 2005), which are a combination of markers 
expressed by organizer cells in the primitive streak region. During subsequent development, 
this triple-positive cell population diverges to Gsc+ and either E-cadherin or PDGFR 
positive intermediates that later differentiate into definitive endoderm and mesodermal 
lineages, including calcified osteopontin expressing osteoblasts (Tada et al., 2005). 
While the mesendodermal progenitors are being established in the process of gastrulation in 
vivo, neurulation has already initiated in the anterior part of the embryo. Therefore, 
specification of neural crest populations may occur in vitro during ESC differentiation at 
around the same time or slightly after T-Brachyury+ or Gsc+ populations are found. In the 
embryo, neural crest cells emerge from the dorsal epithelium of the neural tube after it has 
formed, undergo epithelial-to-mesenchymal transitions and become highly migratory.  
These cells later disperse to and incorporate within skin tissue (i.e. melanocytes) as well as 
neurons and glia in the peripheral nervous system (Chung et al., 2009; Dupin et al., 2007; 
Weston, 1991). Due to the multitude of cell types that arise from the highly specific 
population of neural crest cells, it is sometimes regarded as the fourth germ layer.  In 
addition, the neural crest is generally considered to be the source of a population of cells 
deemed the ectomesenchyme, which produces a variety of mesenchymal tissues including 
craniofacial cartilage and bone (Morrisskay et al., 1993; Smith and Hall, 1990). More recently 
however, the view that mesenchymal cell types are established from progenitor populations 
of neural crest origin was challenged by Weston and colleagues, who suggest that neural 
crest and ectomesenchyme are developmentally distinct progenitor populations, possibly 
distinguishable by the expression of E-cadherin and PDGFR (Weston et al., 2004). 
While it seems widely established that ESCs have the capacity to differentiate into 
osteoblasts from these various origins, other questions related to the feasibility of their 
clinical use are still under investigation. As pluripotent cells, ESCs are particularly attractive 
for the treatment of critical size bone defects that require large numbers of cells as an 
illimitable source of progenitors, be it mesoderm or neural crest derived MSCs or even more 
committed osteoprogenitors. More recently, a new less ethically controversial source of 
pluripotent cells has been discovered in the artificial creation of induced pluripotent stem 
cells (iPSCs). In this method mature, fully differentiated cells are reprogrammed to a 
pluripotent state. Explicitly, pluripotency-associated genes are shuttled into somatic cells, 
e.g. fibroblasts or keratinocytes (Aasen et al., 2008; Okita et al., 2007; Takahashi and 
Yamanaka, 2006), and brought to expression before they are silenced, which is just enough 
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to turn the differentiated cells into ESC-like cells with a pluripotent pheno- and genotype. 
Only five years after their discovery, iPSCs have been recently exploited to study 
osteogenesis and have already been shown to possess comparable differentiation capacity 
(Bilousova et al., 2011). 
3. Bone tissue engineering 
The current gold standard for bone tissue replacement is the autologous graft, which utilizes 
bone tissue that has been extracted from another site within the patient’s own body. 
However, there is only a limited amount of bone tissue that can feasibly be harvested 
without inducing considerable donor site morbidity (Rose and Oreffo, 2002). On the other 
hand, surgical procedures using an allograft, where the bone is harvested from a cadaver, 
can provide enough material to correct large-scale bone defects. However, this approach 
carries its own disadvantages including potential immunorejection and pathogen 
transmission.  Techniques involving synthetic materials such as metals and ceramics are 
continually being used and explored as alternatives to these approaches, but these 
substitutes continually fall short of bone grafts in areas such as host site integration and 
tensile strength (Rezwan et al., 2006; Yaszemski et al., 1996). Thus, the attractive features and 
potential versatility of stem cells offers the investigator an exciting source to improve and 
develop new technologies that may significantly enhance the efficacy of these procedures.  
Currently a popular approach in applying stem cells to de novo bone synthesis is the in vitro 
culturing or ‘seeding’ of cells onto scaffolding materials that can be used for subsequent 
implantation. In order for this approach to be successful there are a number of essential 
properties that a researcher must keep in mind when designing the appropriate scaffolding 
material. These properties will have a direct effect on both the colonization of the scaffold 
and its successful incorporation into host bone tissue. To achieve an optimal scaffold design 
a number of considerations such as biocompatibility, porosity, pore size, osteoinductivity 
and conductivity (including biomolecule incorporation), biodegradability, and mechanical 
properties must be accounted for (Salgado et al., 2004). Thus, reaching this goal will be a 
challenge that requires the coordinated efforts of researches across the diverse disciplines of 
material and biological sciences. 
3.1 Mesenchymal stem cells in bone tissue engineering 
Beyond the type of scaffold used in a particular study, the choice of seeded cell type will 
also play a critical role in the creation of de novo bone tissue. Starting with the most 
differentiated cell type, seeding a scaffold with harvested autologous osteoblasts 
superficially seems attractive because of their inherent cellular program to develop new 
bone. However, using this cell type is problematic because of low initial concentrations 
following harvest and relatively poor proliferation capacity in vitro. Also, if these treatments 
are designed to not only amend bone defects, but also to alleviate bone disorders, it is 
unlikely that harvested osteoblasts will have the suitable characteristics to be effective. 
Another possible cell type is the multipotent adult mesenchymal stem cell.   
Mesenchymal stem cells (MSCs) are unspecialized adult stem cells that reside in mature 
somatic tissues, predominantly the bone marrow in the long bones. There they share the 
niche with hematopoietic stem cells, but differ from them in the array of specialized 
daughter cells that they can generate. MSCs were first described forty five years ago by 
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Friedenstein and colleagues, when they first found this heterogeneity in differentiation 
capacity between cells isolated from bone marrow. While they described the cells as ossific 
progenitor cells of stromal origin in rats in this first study, subsequent studies proved the 
multilineage differentiation potential of these cells into fibroblasts, chondrocytes and other 
cells of connective tissue coining the term mesenchymal stem cell (Friedenstein et al., 1966, 
1976, 1987; Tondreau et al., 2004a, b; Johnstone et al., 1998; Young et al., 1998; Niemeyer et 
al., 2004).  
Despite the fact that the scientific community has long exploited MSCs to understand the 
processes of osteogenic and chondrogenic differentiation as well as for the study of adult 
stem cell maintenance (Bruder et al., 1990; Gazit et al., 1993; Grayson et al., 2006; Hong and 
Yaffe, 2006), the isolation of the non-hematopoietic mesenchymal stem cell from bone 
marrow or other tissue sources remains complex. Initially, Friedenstein isolated the MSCs 
by their tight adherence to plastic (Friedenstein et al. 1976). Yet, newer studies suggest that 
by isolating MSCs based on their plastic adherence, a portion of mesenchymal stem cells are 
lost (Zhang et al. 2009). Unfortunately, the fibroblast-like MSCs show a variable profile of 
surface marker expression (Simmons und Torok-Storb, 1991; Jiang et al. 2002; Vogel et al. 
2003), which makes it difficult to isolate them based on a specific marker set. A few years 
ago, a group of investigators with extensive track records in MSC research has agreed on 
specific characteristics that need to be met by a cell in order to be called an MSC (Dominici 
et al., 2006, the International Society for Cellular Therapy position statement). For example, 
CD14, CD34 or CD45 mark hematopoietic cells and are therefore considered negative 
markers for MSCs. The most commonly used markers for the detection and purification of 
MSCs are CD90 (Thy-1 cell surface antigen), CD105 (endoglin) and CD73 (ecto-5’-
nucleotidase) (Pittenger et al., 1999; Dominici et al., 2006). Both CD105 and CD73 are 
constitutively expressed by MSCs, however are also expressed by endothelial cells (Gougos 
und Letarte, 1988; Airas et al., 1995). Therefore, a combinatorial approach using CD106 
(vascular cell adhesion molecule 1) is also recommended in the literature to identify MSCs, 
as CD106 is only expressed on the MSC surface, but not on endothelial cells (Pittenger et al., 
1999; Osborn et al., 1989). Stro1 (Stenderup et al., 2001), glycophorin A (Pittenger et al., 1999; 
Reyes et al., 2001; Jones et al., 2006), D7-fib (Jones et al., 2002) and p75 (Quirici et al., 2002) 
have also been associated with MSCs recently, but are not contained in the International 
Society for Cellular Therapy position statement.  
Currently, the use of bone marrow derived mesenchymal stem cells (BDMSCs) to study 
bone tissue generation is popular because these can be harvested from the patient’s own 
body, thereby removing concerns of immunorejection and disease transmission. Because the 
transition of BDMSC studies to clinical applications is currently more direct, and not 
enveloped in ethical considerations, there have been many studies looking at the 
differentiation capacity of BDMSCs in vivo (Arinzeh et al., 2003; Bruder et al., 1998; Gao et 
al., 2001; Kotobuki et al., 2008). BDMSCs are already used in preclinical trials for treatment 
of osteogenesis imperfecta and non-union bone fractures (Le Blanc et al., 2005; Tuch, 2006). 
However, this does not exclude the necessity to examine ESCs as a potential source of bone 
engineered cells. In fact, improvements in the techniques of somatic nuclear transfer (Byrne 
et al., 2007) and creating iPSCs (Nakagawa et al., 2008; Yu et al., 2007), make it quite 
plausible that the protocols derived from the study of ESCs may someday become more 
applicable to the future of regenerative medicine than their adult stem cell counterparts. In 
addition, there are drawbacks from using BDMSCs, including the limited number that can 
be obtained, more restricted proliferation and differentiation capacities when compared to 
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ESCs, and they may also harbor undesirable characteristics when harvested from unhealthy 
bone. So although the use of MSCs has progressed further in clinical applications of bone 
tissue engineering, the examination of ESCs as a potential source for repairing bone defects 
and disorders still merits a great deal of attention. 
3.2 Embryonic stem cells for bone tissue engineering 
Since Levenberg and colleagues (2003) demonstrated the potential to create complex tissue 
structures on 3D scaffolds using differentiating human ESCs, a number of investigations 
sought to refine and optimize the conditions required to engineer specific tissue types 
within 3D scaffolds. In 2004, Chaudhry and colleagues (2004) were the first to demonstrate 
the feasibility of inducing mineralization of murine ESC derived cells within 3D poly L-
lactic acid (PLLA) scaffolds. To accomplish this goal the team initially differentiated murine 
ESCs into osteoblast progenitor cells in 2D culture. EBs were initially formed, which were 
then subsequently transferred into suspension dishes for 3 days in the presence of retinoic 
acid, and then were grown in the presence of -glycerophosphate and ascorbic acid. EBs 
were trypsinized and seeded onto PLLA scaffolds. After four weeks of subsequent culture in 
osteogenic media, the scaffolds showed extensive bone nodule formation on the surface of 
the scaffold and evidence of cell invasion/mineralization with the interior, as demonstrated 
by electron microscopy and von Kossa staining. Molecular characterization of the cells that 
had colonized the scaffold also revealed expression of the osteoblast specific markers 
osteocalcin, osteopontin and alkaline phosphatase (Alk Phos).  
When discussing synthetic scaffolds for tissue engineering it is important to realize that not 
only the composition of the material itself is important, but that the nano-scale architecture 
can also play a critical role in the successful colonization of the material.  Smith and colleagues 
(2009) developed a fabrication method of producing a nanofibrous PLLA scaffold in an 
attempt to mimic a collagen matrix. These were compared to traditional ‘solid-walled’ PLLA 
scaffolds in both 2D and 3D osteogenic culture systems. It was found that the 3D nanofibrous 
matrices expedited differentiation of mouse ESCs as revealed by markers runx2, an osteoblast-
specific transcription factor (5 times greater), bone sialoprotein (8.5 times greater) and 
osteocalcin (2.9 times greater). These scaffolds were also found to contain greater amounts of 
COL I (5.5 times) and calcium (3 times) when cultured for 28 days. Another point of interest 
from this study showed that the nanofibrous scaffold, unlike all the other materials tested, was 
also able to support osteogenesis without the addition of osteogenic supplements. Although, 
the osteogenic output was not as robust as when cultured with media supplemented with 
ascorbic acid, -glycerophosphate, and dexamethasone. Thus, it appears that the nano-scaled 
architecture of these scaffolds mimics the endogenous ECM. 
These differences in geometry presumably create a more appropriate spatial context to 
facilitate cell-cell interactions and communication for bone tissue development. In addition, 
it was previously found  that this nanofibrous scaffold absorbed four times the amount of 
serum proteins than their traditional solid walled counterparts (Woo et al., 2003). Thus, the 
ability of this nano-scaled architecture to both improve the spatial arrangement of cells and 
to absorb more growth factors, demonstrates how attention to microscopic manufacturing of 
materials can greatly enhance the potential and success of these scaffolds.   
The availability of a blood supply, especially to large bone grafts, is critical for engineered 
tissue transplant efficacy. The creation of a flap for transplantation is one surgical approach 
to address this issue. A flap is tissue that already has a vasculature system in place to 
support nutrient and gas exchange. Although not explored in ESC-derived grafts, studies 
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performed with BDMSCs demonstrate the feasibility of this approach. Warnke and 
colleagues performed an interesting clinical demonstration of this technique in 2004. Here, a 
seeded scaffold intended to repair a large resection of the patient’s mandible was first 
implanted within the patient’s latissimus dorsi muscle. This in vivo incubation period 
allowed time for the graft, a titanium mesh cage filled with hydroxyapatite blocks coated 
with recombinant human BMP7, to develop vasculature. The graft was initially seeded with 
solution containing autologous bone and natural bovine bone-mineral extract. After seven 
weeks the implant was removed along with the muscle tissue containing the thoracodorsal 
artery and vein, which had provided the circulation to the implant, and was transplanted 
into the patient’s jaw. Bone mineral density was measured using non-invasive 3D 
chromatography and revealed continuous improvement for the duration of 38 weeks 
(Warnke et al., 2004). Due to ethical considerations, a biopsy of the implant was not 
undertaken. However, mineralized scar tissue in areas of implant overgrowth was 
histologically examined and showed young cancellous bone formation containing viable 
osteoblasts and osteocytes. The patient’s continual smoking and alcohol abuse compromised 
the initial favorable prognosis of the treatment, and unfortunately the patient had passed 
away 15 months following the operation (Warnke et al., 2006). Also due to the nature of the 
procedure, which precluded the use of control implants, statistical analyses were not 
performed. However this study provides at least an initial demonstration of principle within 
a human subject, and may eventually serve as a model to vascularize engineered bone tissue 
in vivo.   
To examine the differences in the in vivo osteogenic capacity of between BDMSCs and ESCs, 
Tremoleda and colleagues (2008) implanted chambers that were cell-impermeable. These 
chambers contained either BDMSCs or ESCs that had been cultured in vitro for 4 days in 
standard osteogenic media. Since the pore size of these chambers precluded the passage of 
cells but allowed the diffusion of growth factors and other macromolecules, comparison of 
the intrinsic capacity for differentiation of these cell types became more straightforward. 
After 79 days post-implantation within nude mice, the authors reported no qualitative 
differences between the bone tissue formation between the BDMSCs, H7, and H9 embryonic 
stem cells. Although an interesting finding revealed that the ESC lines used did not require 
the in vitro osteogenic culture prior to implantation to form de novo bone tissue, which was 
unlike the BDMSCs, which required this pretreatment. Thus, although a significant 
difference between these cell types with the same osteogenic treatment was not uncovered 
in this study, the fact that ESCs required less coaxing and were more primed to respond to 
the bone tissue environment may be capitalized upon in future studies. 
However, one of the major concerns when using ESCs for reparative medicine is the 
potential for residual undifferentiated cells to form teratomas following in vivo introduction. 
As such, undifferentiated murine ESCs form teratomas when injected into a healthy knee 
joint (Wakitani et al., 2003). The rate at which the teratomas grew in the knee joint however 
was slower than upon subcutaneous injection, suggesting that the microenvironment in the 
knee joint is not as favorable for ESC proliferation as for example a subcutaneous injection 
site. Surprisingly, if cells were injected into an inflammatory environment caused by a full-
thickness osteochondral defect, the cells integrated and repaired the defect even in an 
allogenic setting (Wakitani et al., 2004).  
Also, our group was recently able to show that ESCs lose their teratoma formation capacity 
with progressing osteogenic differentiation and maturation in vitro, whereby the in vitro 
microenvironment used to steer differentiation influences their teratoma formation capacity 
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in vivo. Whereas spontaneously differentiated cells formed teratomas in 16% of the cases 
when taken from day 10 old cultures, 30-day osteogenic cultures did not show any sign of 
teratoma formation upon subcutaneous injection (Taiani et al., 2009).  
Highlighting the concern of teratoma formation further, Nakajima and colleagues (2008) 
seeded mouse ESCs embedded in a collagen matrix into osteochondral defects within the 
knee joints of mice. Their investigation focused on the differentiation potential of these cells 
when the joint was either free to move or physically immobilized. They revealed that the 
mechanical environment appears to have a dramatic effect on the differentiation outcome of 
these implanted cells. Three weeks post operation, the defects were examined and the free-
moving joints were shown to contain cartilaginous tissue formation with favorable 
histological characteristics. Surprisingly, when the joint was immobilized a teratoma formed 
in every instance of study. Thus, considering the close link between chondrogenesis and 
osteogenesis (to be discussed further in next section), it is important to note the results here 
and recognize that the mechanical environment into which undifferentiated stem cells are 
placed can have important consequences. 
3.3 ESC-derived MSCs 
Another cell type that has been recently gained attention as a possible therapeutic source is the 
embryonic stem cell-derived mesenchymal stem cell (ESC-MSC) in which ESCs are induced 
along the mesenchymal stem cell lineage. For a more detailed overview of the markers and 
techniques used to isolate such mesenchymal stem cell like cells from ESCs, the reader is 
referred to two recent reviews by Hematti (2011) and zur Nieden (2011). In one study of this 
cell type Barberi and colleagues (2005) demonstrated that cells initially differentiated along a 
paraxial mesoderm lineage were able to undergo osteogenesis in vitro. They found that this 
induced and sorted cell type (i.e. using the mesenchymal stem cell marker CD73) was able to 
undergo osteogenesis, by various staining assays and expression of bone specific markers. 
Similarly, Hu and colleagues derived human ESC-MSCs, and examined their capacity to 
differentiate into bone forming cells (Hu et al., 2010). When these cells were cultured in the 
presence of dexamethasone and BMP-7, they found that both Alk Phos levels and calcium 
deposition was statistically higher in dishes containing both supplements. This improvement 
found with both supplements was a synergistic one, as revealed through the modest effect 
when BMP-7 was used independently. When these cells were grown on 3D PLLA nanofibrous 
scaffolds, similar to that of Smith and colleagues (2009) discussed earlier, they exhibited 
growth throughout the scaffold and demonstrated extensive mineralization.   
The in vitro osteogenic capacity between isolated human MSCs and derived human ESC-
MSCs, was directly compared by de Peppo and others (2010). In this study they designated 
human ESC-MSCs as human embryonic stem cell-derived mesodermal progenitors hES-
MPs and used a similar approach to that of Hu et al. (2010) to derive this cell type (Karlsson 
et al., 2009). Here they demonstrated that in vitro culture of hES-MPs resulted in faster ECM 
mineralization as compared to human MSCs. These results were contrary to their Alk Phos 
assays, which showed significantly greater activity of Alk Phos in human MSCs at every 
point during the first five weeks of differentiation. This apparent discrepancy may reflect a 
differential dependence of Alk Phos to mineralize the ECM between these cell types. In 
addition, this study examined the osteogenic capacity of cells in relation to their passage 
number. In every assay performed the osteogenic capacity decreased as passage number 
increased for all cell types examined. Although they reported that the hES-MPs were more 
buffered against this diminishing capacity, it brings attention to the problem with serial 
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passages, which are inexorably tied to the requirements of tissue engineering, and their 
resulting potential to undergo osteogenesis.  
The apparent discrepancy in relative Alk Phos activity was also found by Bigdeli and others 
(2010) when they compared the osteogenic capacity of human MSCs and a derived human 
ESC line (Bigdeli et al., 2008), which could be expanded on culture plastic without the 
support of feeder layers or other dish coatings such as Matrigel. Utilizing this cell line 
allowed the investigators to perform more direct comparison of the two cell types, since the 
typical differences between culture conditions were eliminated. Like the aforementioned 
study (de Peppo et al., 2010), they found that although Alk Phos expression was 
significantly lower at each time point examined, the derived human ESC line was better able 
to mineralize the extracellular matrix when compared to human MSCs. These results were 
further supported by ion mass spectrometry of the mineralized ECM, which demonstrated 
the signature of natural hydroxyapatite.  
A study comparing osteogenesis of murine MSCs and murine ESCs derived from the same 
mouse strain (Shimko et al., 2004) also revealed this pattern where the mineral content was 
not directly correlated to Alk Phos activity. Thus, although Alk Phos activity is used 
frequently in studies of osteogenic differentiation, the level of enzyme activity may not 
directly correspond to the potential of the cells to mineralize the extracellular matrix. In 
addition, diverse Alk Phos levels may not necessarily suggest that more or less osteoblasts 
were formed, but may simply reflect different maturation kinetics of the different cell types.  
Shimko et. al, (2004) went further in characterizing the mineralized matrix between murine 
MSCs and murine ESCs derived from the same mouse strain and cultured in the same 
conditions. As compared to natural hydroxyapatite found in bone, where the ratio of 
calcium to phosphorous is: 1.67:1; murine ESCs exhibited a ratio far closer (1.26:1) than 
murine MSCs (0.29:1). Mouse ESC cultures also contained, on average, a mineral content 50 
times greater than mouse MSCs. However, once again reflecting distinct differentiation 
kinetics, pathways, or inherent differences in mineralization capacity, Alk Phos activity was 
significantly higher in MSCs throughout the course of the experiment. In addition, 
expression of osteocalcin and COL I in mouse ESCs was delayed relative to mouse MSCs. 
Thus, murine MSC differentiation appeared to be more reflective of natural osteogenesis, 
when examining organic matrix components and gene expression. On the other hand, the 
quantity and quality of the mineralization found in murine ESCs significantly surpassed 
what was exhibited by murine MSCs.   
Although transferring the techniques of osteogenic induction of ESCs from flat culture 
dishes towards 3D scaffolds have demonstrated initial success, there continues to be the 
need for method refinement in order for these approaches to bone engineering become 
widely accepted. One such area of study where current knowledge is lacking is an 
understanding of the possible differentiation pathways that are normally found in 
vertebrate development these cells take in attempts at bone tissue engineering. 
4. Different embryonic bone origins 
Both in vitro and in vivo studies continue to elucidate the developmental program that 
pluripotent stem cells take to their eventual differentiated states, among them the osteoblast. 
Because of their capacity to differentiate into any cell type of the body, pluripotent stem cells 
may differentiate through the neural crest route or the mesodermal route, followed by 
mesenchymal specification. Similarly, ossification from pluripotent stem cells may occur 
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through intramembranous bone formation or endochondral bone formation. In regard to the 
in vivo source of mesenchymal cells, which differentiate into bone in the appropriate 
developmental context, there also appears to be multiple developmental origins. The earliest 
MSCs appear to arise from Sox1+ neuroepithelium through a neural crest intermediate stage 
(Takashima et al., 2007) and not from mesoderm progenitors as previously believed.   
The process of fracture healing also occurs through both intramembranous and 
endochondral means, which is dependent on the mechanical conditions at the fractured site 
(Claes et al., 1998). When dissecting the steps of bone development, far more is known about 
the endochondral pathway than the intramembranous process. The most overt difference 
between these two pathways is that either chondrocytes will arise from mesenchymal 
condensations, which subsequently apoptose and are replaced by invading osteoblasts, or 
there is a direct differentiation into osteoblasts themselves. Thus the differential influence 
and the necessity of chondrocytes highlight the most apparent differences between these 
bone-forming pathways. Thus, in order to optimize bone tissue-engineering procedures 
there is a need to understand the molecular basis underlying different bone formation 
processes. However, a current review of the literature demonstrates large holes in our 
understanding of these multiple routes in which bone naturally forms and how they are 
recapitulated in experimental systems. The remaining part of this chapter will be devoted 
towards our preliminary understanding of these processes with particular emphasis to their 
roles in bone tissue engineering.  
4.1 Endochondral ossification 
In the endochondral process mesenchymal cells condense and differentiate into proliferating 
chondrocytes, which take on the general shape of the future bone. These chondrocytes 
eventually fall out of the cell cycle and these post-mitotic chondrocytes undergo 
hypertrophy. In this stage of development the mature hypertrophic chondrocytes lay down 
cartilage-specific proteins into the surrounding matrix. This cartilaginous framework 
provides molecular cues, which attracts invading vasculature along with osteoblasts, which 
will replace the cartilage intermediate. Osteogenesis occurs directly adjacent to hypertrophic 
chondrocytes. It appears that both the parathyroid hormone (PTH)-related peptide (PTHrP) 
and its receptor PPR are critical in the process osteogenesis via the endochondral pathway. 
In mice, upon disruption of the either PTHrP or PPR, the formation of ectopic hypertrophic 
chondrocytes is accompanied by ectopic bone collar formation (Karaplis et al., 1994). To 
determine if the hypertrophic chondrocytes induce osteogenesis in adjacent cells and is not a 
spatial/temporal coincidence, Chung and colleagues (2001) studied transgenic mice that 
express constitutively active PPR under the control of a chondrocyte specific promoter. This 
constitutive action resulted in suppression of hypertrophic chondrocyte formation and 
concurrent suppression of bone collar and primary spongiosa development. In addition, 
when these transgenic mice were mated to PTHrP-/- mice the resulting rescue of the ectopic 
bone formation, supported the conclusion that hypertrophic chondrocytes are responsible 
for the induction of osteogenesis in adjacent tissue. 
Regulation of the PTHrP/PPR signal appears to be controlled by one of the members of the 
hedgehog family of paracrine factors, Indian hedgehog (Ihh). Members of this signaling 
family are found throughout the animal kingdom and take on a number of critical roles in 
the developing organism. Here, Ihh is expressed by both prehypertrophic and hypertrophic 
chondrocytes. This signal mediates the expression of PTHrP by cells of the perichondrium, 
which in turn binds to PPR on chondrocytes. Ihh and PTHrP signaling thereby creates a 
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negative feedback loop which suppresses differentiation of the proliferating chondrocytes 
into hypertrophic ones (Lanske et al., 1996; Vortkamp et al., 1996). Thus, this balance of 
signals dictates the spatial positioning of the hypertrophic chondrocytes. However, the role 
of Ihh appears to have a broader impact on osteogenesis than its PTHrP-dependent 
regulation of chondrocyte maturation.  
St-Jacques and colleagues (1999) demonstrated that Ihh also plays a role in chondrocyte 
proliferation and the direct development of osteoblasts in endochondral bones. Previous 
studies have demonstrated a critical role of Wnt signaling and -catenin localization as well 
(Gong et al., 2001; Kato et al., 2002). Hu and others (2005) found nuclear -catenin 
localization within the cells of perichondrium indicating an upstream role of Ihh signaling 
to facilitate proper Wnt signaling. Furthermore, Ihh null mice do not exhibit osteocalcin 
expression within endochondral bones, whereas this expression is readily detected within 
the intramembranous bones of the skull and clavicle. This differential dependence of Ihh 
signaling underscores one of the differences between endochondral and intramembranous 
bone formation.   
When assessing the role of local synthesis of VD3 in transgenic mice that exhibited a 
chondrocyte-specific loss-of-function Cyp27b1, the enzyme that converts 25-hydroxyvitamin 
D3 into the active form VD3, it was found that the hypertrophic zone was expanded (Naja et 
al., 2009), thereby increasing both bone mass and trabecular size and number. The classical 
view that VD3 synthesis (active form) was restricted to the kidneys and that this hormone’s 
influence on bone tissue regulation was an indirect consequence of altering calcium and 
phosphate homeostasis had to be reevaluated. The authors suggest their results can be 
explained by a reduced osteoclast recruitment, which follows from a reported delay of 
vascularization that may be attributed to a reduction of VEGF found.  Conversely, 
overexpression of Cyp27b1 under a chondrocyte-specific promoter resulted in the opposite 
expression profile and phenotype. These results are in accordance with chondrocyte specific 
VD3 receptor ablation experiments, which showed impaired vascularization and osteoclast 
number in endochondral bone (Masuyama et al., 2006). As opposed to the traditional view of 
the role of VD3 in bone biology as an indirect mediator of mineral uptake, these experiments 
demonstrate a functional role of this metabolite in regulating endochondral bone formation. 
Some investigators have explored an approach to bone tissue-engineering by mimicking the 
development of mammalian long bones, where the creation of cartilage scaffolds in vitro are 
implanted in vivo. This approach hinges on the idea that the body will recognize this 
cartilage scaffold as an intermediate step in the endochondral bone formation process and 
will then proceed to ossify this construct. In the formation of endochondral bone, 
chondrocytes are exposed to very low oxygen levels and their survival is dependent on the 
expression of the transcription factor hypoxia-inducible factor-1 (For review see: Pfander 
and Gelse, 2007). Thus, the natural ability of chondrocytes to withstand the low oxygen 
supply can provide the time needed for new vasculature to develop and reach the core of 
the implant before widespread cell necrosis.  
Jukes et al. (2008) tested whether in vitro differentiation of ESCs along chondrocyte lineages 
on scaffolds could improve in vivo osteogenesis following implantation. ESCs were initially 
induced along a chondrogenic pathway for 21 days on ceramic scaffolds. These 
chondrogenically-primed scaffolds were then subsequently implanted in immunodeficient 
mice and were found to exhibit nascent bone tissue formation when examined 21 days post-
operatively. For comparison, primary chondrocytes and adult MSCs of human, goat, and 
bovine origin were used in lieu of the chondrocyte-induced ESCs. It was found that each cell 
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type demonstrated differential abilities to form bone tissue in vivo. Interestingly, the goat 
MSCs resulted in the highest degree of bone tissue formation, and it appeared that this 
formation occurred via an intramembranous pathway.  
Farrell et al. (2009) further examined the in vitro chondrogenic-priming of scaffolds using 
human MSCs and reported limited success. After the cells were cultured on collagen–GAG 
scaffolds for three weeks in chondrogenic media, the scaffolds were implanted 
subcutaneously in nude mice. Although cell survival and angiogenesis was found higher in 
the chondrogenically-primed scaffolds, as opposed to scaffolds that were osteogenically-
primed, there appeared to be no de novo osteogenesis. The authors reported the 
chondrogenically-primed scaffolds showed evidence of the initial progression of 
endochondral ossification, yet were unable to proceed through the later stages of osteoblast-
induced mineralization. When mineralization was induced in vitro prior to implantation, the 
nascent angiogenesis that was previously obtained was compromised. Thus, it appears that 
for this approach to be successful, the timed release of additional factors in vivo is needed to 
promote the osteogenic replacement of the cartilaginous scaffold.   
When examining the developmental pathway of bone-tissue engineered constructs, by 
either endochondral or intramembranous routes, it makes sense that different cell types will 
mature along different pathways even when presented to the same conditions. Tortelli and 
others (2010) revealed how the differentiated state of implanted cells affects subsequent 
ossification and host cell recruitment to the graft site. They seeded hydroxyapatite scaffolds 
with either human MSCs or osteoblasts. When differentiated osteoblasts were used to seed 
the scaffolds, ossification occurred through an intramembranous pathway, as revealed by 
the lack of cartilage markers by immunohistological examination. This intramembranous 
ossification appeared to be more rapid and thus accounted for more bone deposition within 
the same time period when compared to the MSC-seeded scaffolds. However, MSC 
scaffolds, which ossified in an endochondral fashion, were able to facilitate nascent 
vascularization of the graft. This highlights the fact that engineered bone grafts may one day 
be tailored to a patient’s need depending on factors such as speed of graft ossification and 
site incorporation. In addition this study shows that implanted MSCs can progress through 
the endochondral pathway, but as the aforementioned study by Farrell et al. (2009) 
demonstrates this process currently cannot be split into an early in vitro stage that can be 
‘picked up’ later in vivo. However, if the process of endochondral bone formation is 
elucidated further and applied to tissue engineering, then it is feasible that this approach 
may one day become a viable avenue to repair large bone defects. 
Although mimicking the development of long bone through endochondral ossification of 
scaffolds maybe appropriate in some contexts, intramembranous ossification may be 
suitable for other applications in regenerative medicine. The body utilizes both of these 
systems in different contexts depending on certain conditions whose reasons remain to be 
fully characterized. Nonetheless, it appears quite probable that bone tissue engineering need 
not only be tailored to the individual but also the specific bone defect or disease in order to 
be completely effective.  
4.2 Intramembranous ossification 
As for intramembranous bone formation, not only is little known about the process itself, 
but the developmental pathway of the cells leading to the formation of the tissues within the 
cranial skeleton is still not well understood.  
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4.2.1 Neural crest cells  
As incipiently indicated, the migrating cranial neural crest cells form bone mostly through 
intramembranous ossification. Initially neural crest cells become committed to either an 
ectomesenchymal (i.e. producing tissues such as cartilage, bone and connective tissue) or a 
non-ectomesenchymal (i.e. producing neurons, glia and pigment cells) lineage. The 
ectomesenchymal tissue is also referred to in the literature as mesectoderm. Blentic and 
others (2008) describe how migrating neural crest cells in chick and zebrafish embryos 
commit to either fate.  Cells that migrate into the pharyngeal arches are induced to respond 
to FGF signaling within these embryonic structures, resulting in the expression of the 
homeobox gene Dlx2. Concurrently, early neural crest markers Sox10 and FoxD2 are 
downregulated, which are still expressed in the neural crest cells that have not invaded the 
pharyngeal arches and thus are fated to become non-ectomesenchyme. Whether or not 
neural cells migrate into the pharyngeal arches appears to be determined by the timing of 
their emergence from the neural tube. Although not fully understood, it appears that early 
migrating cells ‘fill up’ the pharyngeal arches and the cells that migrate later are thus more 
likely to find residence outside of the arches and become non-ectomesenchyme (Blentic et 
al., 2008). 
4.2.2 Neural crest and mesodermal progenitors in intramembranous bone formation 
The parietal bone, which is of paraxial mesoderm origin and the frontal bone, which is of 
neural crest origin, both form via intramembranous ossification, thus making the study of 
calvarial bones an attractive platform to study the possible differences in bones of different 
embryonic origins.  Quarto et al. (2010) examined the osteogenic capacity of first passage 
osteoblasts that were obtained from these respective bones in mice. Frontal bone-derived 
osteoblasts from post-natal day 7 and day 60 mice were found to exhibit greater 
mineralization capacity, as revealed by Alk Phos activity, von Kossa and Alizarin Red S 
staining. This was also supported by expression data of the bone-specific markers 
osteocalcin and runx2. These in vitro observations were reinforced by the relative healing 
capacity of these two bones. The successful healing of 2mm defects was found within the 
frontal bone in the majority of mice at 8 weeks post-injury, whereas complete healing was 
not typically found in same sized injuries of the parietal bones within the same time period.  
The investigators uncovered a higher level of endogenous canonical Wnt signaling in frontal 
bone osteoblasts as compared to parietal bone osteoblasts that may be responsible for this 
differential regenerative propensity. By modulating Wnt signaling through exogenous 
addition of Wnt3a or transfecting osteoblasts with constructs that increase -catenin 
signaling in parietal bones to frontal bone levels, and vice versa, the authors showed a 
reversal of osteogenic potential of these cells. Thus, providing strong evidence that that the 
enhanced osteogenic potential of frontal bone osteoblasts can be at least be partially 
attributed to these differences in endogenous Wnt signaling.  
Xu and colleagues (2007) found that osteoblasts derived from the frontal bone proliferated 
faster and attached to culture dishes better than osteoblasts that were harvested from 
parietal bone. This may be linked to the fourfold greater expression of osteoblast-specific 
cadherin that they found within frontal bone osteoblasts. The parietal bone osteoblasts did 
however show double the Alk Phos activity at the time points examined. When cultured in 
the presence of osteogenic inducing factors, such as VD3, the frontal bone osteoblasts 
showed a much more robust bone nodule formation. However, expression of osteogenic 
differentiation markers, such as osteopontin, Col1, and Wnt5a was significantly greater in 
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the parietal bone derived cells. Members of the FGF signaling cascade were also 
differentially expressed between these two cell types. Thus, the frontal and parietal bones 
appear superficially similar yet exhibit an number of different characteristics such as growth 
kinetics, regulation by signaling cascades and varying marker expression, all of which 
demonstrate that these bones are not as similar as they initially appear to be.  
To further examine the regenerative osteogenic capacity of cells from different embryonic 
origins Leucht and others (2008) engineered mice in which developing cells of neural crest 
origin would irreversibly express GFP. Tissues from mesodermal origin were also induced 
to express β-galactosidase. Following skeletal injury in either the mandible or the tibia 
resulted in natural bone regeneration where the progenitor pool which became new bone 
tissue was derived from the same embryonic origin of the injured bone itself (i.e. cells from 
neural crest origin repaired mandible defects, and cells of mesodermal origin repaired tibia 
defects). The investigators then performed a number of transplant experiments where 
skeletal progenitor cells were implanted into bone of different embryonic origin. 
Interestingly neural crest derived progenitors were able to form more new bone when 
implanted ectopically into tibia injury sites, than if they were implanted back into their 
endogenous environment within mandible injuries. Conversely, when mesoderm derived 
progenitors were implanted into mandible injuries, an abundance of cartilage formed, 
which over time ossified via an endochondral pathway.  
These results suggest a difference in the underlying reparative plasticity of cells from 
different origins. In vitro analysis demonstrated that mesoderm osteoprogenitors 
proliferated faster than the corresponding neural crest osteoprogenitors. However, the cells 
of neural crest origin were able to differentiate faster based on Alizarin Red S staining and 
qPCR of osteogenic markers. The authors went further to try to understand the possible 
molecular mechanisms underlying this difference (Leucht et al., 2008). They found that in 
the adult mice Hoxa11 expression was maintained in the tibia and was absent in the 
mandible. For neural crest osteoprogenitors, which originally lack Hoxa11 expression, they 
began to express Hoxa11 when ectopically placed in the tibia. This switch in expression was 
not found in the mesodermal osteoprogenitors, which continued to express Hoxa11 even 
when placed in the Hoxa11-negative environment of the mandible. This study once again 
reiterates how the molecular identity of cells used for transplantations can be a crucial factor 
in determining the success of a stem cell based bone graft. In addition, it may be true that 
osteoprogenitors of neural crest origin may be best suited as the stem cell source of bone 
grafts because of their greater plasticity to adapt to local environments.   
4.2.3 ESC-derived neural crest stem cells 
When ESC cultures are osteogenically induced following standard differentiation 
procedures, it is seldom examined which developmental progenitors are responsible for the 
terminally differentiated osteoblasts. Although some studies have differentiated ESCs along 
defined lineages and then determined their osteogenic capacity, Lee et al. (2008) reported 
the isolation and propagation of human neural crest cells from human ESCs. Initially they 
cultured human ESCs in neural induction media and then mechanically removed and 
replated the resulting neural rosettes. Cells that were doubly positive for the neural crest 
markers p75 and HNK-1 were further cultured and revealed a CD73 positive population. 
This marker expression indicates the presence of neural crest-derived mesenchymal stem 
cells. This CD73+ population could be osteogenically induced as revealed by Alizarin Red S, 
and Alk Phos staining, and bone sialoprotein expression.  
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In a similar study Jiang and colleagues (2008) also used a FACS enrichment strategy for p75 
and HNK-1 positive neural crest cells after co-culture of human ESCs with PA6 stromal 
cells, although the osteogenic differentiation potential of such isolated neural crest cells was 
not determined. In another study cranial neural crest-like cells were derived from human 
ESCs, not by co-culture but instead though EB formation (Zhou and Snead, 2008). Here, 
FACS purification of neural crest cells was performed based on the expression of Frizzled3, 
a Wnt receptor, and cadherin11, a cadherin specifically expressed in the gastrulating embryo 
and migrating neural crest cells (Kimura et al., 1995). Only about 1% of cells were double 
positive for these selected markers and were able to self-renew and maintain multipotent 
differentiation potential, including runx2 positive osteoblasts with the capability to calcify. 
Although not definitive demonstrations of the isolation of osteoprogenitor stem cells from 
different germ layer-derived populations, these studies offer compelling evidence that cells 
existing in in vitro culture conditions can recapitulate the neural crest osteogenic pathways 
found in the developing embryo.  
5. Conclusion 
In summation, pluripotent stem cells are a particularly attractive source to develop new 
technologies and techniques to address many debilitating bone disorders and defects, and 
we have come far in the understanding and characterization of osteogenesis. Although more 
investigations and innovations are needed before regenerative bone biology becomes 
commonplace, the future holds great promise in this field of research.   
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